Trial Profile

A Phase 2a, Observer-Blind, Randomized, Controlled, Age-De-Escalation, Single-center Interventional Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella (iNTS) Disease and Typhoid Fever, Including Dose and Schedule Finding in Infants, in Africa

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 02 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GSK 4077164A (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate; Pneumococcal 13-valent CRM197 vaccine conjugate; Pneumococcal 7-valent CRM197 vaccine conjugate; Typhoid vaccine
Indications Salmonella infections; Typhoid
Focus Adverse reactions; Pharmacodynamics
Sponsors GSK

21 Jan 2026 Planned initiation date changed from 17 Dec 2025 to 16 Feb 2026.
23 Dec 2025 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com